Heart transplantation has a one-year survival rate of about 87% and a median survival of 12 to 13 years, making it the most effective treatment for end-stage heart failure. Those numbers have steadily improved over the past two decades, and certain groups, particularly young children, now live more than 20 years with a transplanted heart. How long and how well someone does depends on a mix of donor factors, recipient health, and what happens in the years that follow surgery.
Survival Rates by the Numbers
Looking at large registry data, one-year survival after heart transplant sits at roughly 87%, five-year survival at about 73%, and ten-year survival around 54%. These figures include transplants from older donors and higher-risk recipients, so individual odds can be substantially better or worse depending on circumstances. The median survival of 12 to 13 years means half of all recipients live longer than that, and many reach 20 years or more.
Children tend to do especially well. Infants transplanted before their first birthday have a median survival of 22.3 years. For children aged one to five, median survival is 18.4 years; for ages six to ten, 14.4 years. Among kids under ten who make it through the first year, 83% are still alive a decade later. The younger immune system adapts more readily to the new organ, though it also requires lifelong medication to keep rejection in check.
What Affects Your Odds
Not every transplant carries the same level of risk. Several factors on both the donor and recipient side shift the probability of long-term success. On the donor side, hearts from donors over 45 can perform well as long as there is no significant coronary artery disease and the time the heart spends without blood flow (ischemic time) stays under four hours. When ischemic time stretches beyond four hours, the risk of complications rises. Donor smoking history and certain viral infections in the donor also modestly increase risk.
Recipient factors carry more weight. Being over 55, having diabetes, obesity, or needing dialysis or a ventilator before surgery all raise the hazard meaningfully. Prior cardiac surgery also adds complexity. The combination of these factors matters more than any single one, which is why transplant teams evaluate each case individually rather than relying on a single cutoff.
The First Year: Rejection and Early Risks
The first twelve months after transplant are the most critical. About 12% of recipients experience acute rejection during this period, even with modern drugs that suppress the immune system. Rejection means the body’s immune cells attack the transplanted heart, and it can range from mild (detected only on biopsy, no symptoms) to severe and life-threatening. Routine monitoring catches most episodes early, and the vast majority respond to treatment adjustments.
Early graft failure, where the new heart simply doesn’t function adequately in the first days after surgery, is the leading cause of death in the immediate post-operative period. Infection is another major early threat because the immune-suppressing medications that prevent rejection also leave recipients vulnerable to bacteria, viruses, and fungi. These risks diminish significantly after the first year as medication doses stabilize and the body adjusts.
Long-Term Challenges
The biggest long-term threat to a transplanted heart is a condition called cardiac allograft vasculopathy, a gradual narrowing of the blood vessels inside the donor heart. It develops in about 30% of recipients by five years and nearly 50% by ten years. Unlike typical coronary artery disease, it affects the entire length of the blood vessels rather than forming discrete blockages, which makes it harder to treat with stents or bypass surgery. It is the main reason some recipients eventually need a second transplant.
Cancer is another significant long-term concern. Years of immune suppression increase the risk of certain malignancies, particularly skin cancers and lymphomas. Recipients undergo regular screenings, and catching these early makes a substantial difference. Kidney damage from long-term use of immune-suppressing drugs is also common, and some recipients eventually need kidney-related treatment as well.
When researchers looked at which causes of death stole the most life years from transplant recipients, acute graft rejection topped the list, largely because it tends to strike younger patients. The median age at transplant for those who died from acute rejection was just 23, and they survived a median of five years post-transplant. Chronic rejection, organ failure, cancer, and infection followed in terms of total life years lost.
Quality of Life After Transplant
Survival numbers only tell part of the story. Before transplant, most recipients are severely limited, unable to walk across a room without becoming breathless. Afterward, the improvement is dramatic. In a study of patients 20 to 31 years after their transplant, nearly 96% were in the two mildest functional categories, meaning they had no symptoms at rest and only mild limitations during physical activity. Only about 15% showed reduced heart pumping function on imaging.
Most recipients return to work, exercise, travel, and live independently. Some compete in athletic events. The daily reality does include taking multiple medications, attending regular clinic appointments, and undergoing periodic heart biopsies or imaging to check for rejection or vessel disease. That routine becomes familiar quickly, and most people consider it a manageable trade-off.
New Technology Is Expanding the Donor Pool
One of the biggest barriers to heart transplant success has always been the shortage of donor organs. A portable perfusion system (often called “heart in a box”) is changing that equation. The device keeps a donor heart warm and beating outside the body, pumping it with oxygenated blood during transport. This technology is the only approved method for preserving hearts donated after circulatory death, a category of donors that was previously unusable for heart transplant.
The results have been striking. In FDA review data, hearts preserved this way had a 93.8% patient survival rate at one year, compared to 87.9% for conventionally preserved hearts from brain-dead donors. The utilization rate of these previously unusable hearts was nearly 88%, meaning the technology successfully converted most of them into viable transplants. For patients on the waiting list, this translates directly into shorter wait times and more lives saved.
Children vs. Adults: How Outcomes Differ
The underlying diagnosis matters, particularly in children. Kids transplanted for cardiomyopathy (a disease of the heart muscle) had 88% survival at three years, compared to 79% for those with congenital heart defects. By ten years, the gap closed to about 70% and 68%, respectively. Children with single-ventricle heart defects who had undergone prior staged surgeries fared worse, with 53% ten-year survival. Myocarditis, an inflammatory condition, carried a one-year survival of 83% and three-year survival of 65% when it led to transplant.
For adults, age at transplant is one of the strongest predictors. Recipients over 55 face a 37% higher risk of death compared to younger adults. Diabetes adds 27% more risk, and obesity adds 20%. None of these factors are absolute disqualifiers, but they help explain why published survival statistics represent averages across a wide range of individual situations. A healthy 40-year-old with no complicating conditions will generally do considerably better than the overall numbers suggest.